Detecting kidney DNA in transplant patients with potential rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify and characterize kidney transplant rejection by analyzing circulating DNA in the blood of patients facing graft rejection episodes. It leverages the epigenetic properties of circulating DNA to provide a non-invasive diagnostic alternative to traditional biopsy methods. The study involves patients who are scheduled for a kidney biopsy at specific hospitals in Paris and seeks to improve the understanding of graft dysfunction through innovative diagnostic techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 ans
* Patient living with at least one functioning kidney graft
* Summoned to perform a kidney biopsy for cause/indication at the Pitié Salpêtrière Hospital or at the Necker Hospital
* Having been informed of the study and not opposing the study
* Benefiting from a social security system (excluding AME)

Exclusion Criteria:

* Under legal protection measure (curatorship or guardianship, under judicial protection).

Where it's running

• Assistance Publique - Hôpitaux de Paris, Hôpital Necker
  Paris, France Recruiting
• Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière hospital
  Paris, France Active not recruiting
• Assistance Publique - Hôpitaux de Paris, Hôpital Tenon
  Paris, France Not yet recruiting

Study contacts

• Principal investigator: Pierre GALICHON, Pr — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Pierre GALICHON, Pr
• Email: pierre.galichon@aphp.fr
• Phone: 1 42 17 72 29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Finding the right steroid dose for acute T cell rejection after kidney or kidney–pancreas transplant

  This trial will test whether lower doses of steroids work as well as higher doses to treat acute T cell–mediated rejection in people who have had a kidney or simultaneous kidney–pancreas transplant.

  Recruiting at 2 sites Phase 3 University of Sydney · Lambton, New South Wales and 29 other locations · NCT06474273

• Immune biomarkers to predict complications after liver transplantation

  This study tests immune biomarkers in adults after liver transplant to see if changes in markers relate to infections, rejection, or viral reactivation within the first year.

  Recruiting at 3 sites Hospital Italiano de Buenos Aires · Pilar, Buenos Aires and 2 other locations · NCT07875595

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• Non-invasive test to predict early heart rejection in pediatric transplant patients

  This study tests non-invasive heart tests like cardiac MRI and blood markers to see if they can detect rejection in kids after heart transplant, potentially reducing the need for invasive biopsies.

  Recruiting at 22 sites Vanderbilt University Medical Center · Little Rock, Arkansas and 21 other locations · NCT07770659

• How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors

  This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.

  Recruiting University of Gaziantep · Gaziantep, Sahinbey · NCT07760402

• Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers

  This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.

  Recruiting University of Gaziantep · Gaziantep, State/Province · NCT07678073

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.